cms.bioaccessla.com

Category: Preparing for First-In-Human Studies

Offers insights and best practices for Medtech, Biopharma, and Radiopharma companies preparing for their first-in-human clinical trials.

  • How a Startup Buys Trial Liability Before the First Site Is Chosen

    General information, not insurance, legal, or regulatory advice. Confirm current ethics / national authority ethics, import, and coverage rules with qualified advisers and a licensed broker. We do not invent premiums, limits, or carrier rates on this page. We do not claim a named carrier as a signed bioaccess® partner here. No patient data. No unpublished client. Always bioaccess®.

    If you searched how startups buy trial liability before first site, bind clinical trial insurance before site selection FIH, you were looking for someone who would write international clinical-trial coverage for an investigational device. bioaccess® is a first-in-human medical-device CRO. We are not an insurance carrier. We do not underwrite policies. We do not sell premiums. We do not quote a binder. OUS and Latin American device trials still need trial-specific liability — local admitted paper, a master with local certificates, or both. We run the trial under ISO 14155. We can introduce a specialty carrier. That introduction is not a signed partnership on this page, and it is not a quote.

    Boards ask for insurance before they approve a country. Ethics asks for a named site on the certificate. Those two clocks fight. The move is not to skip paper. The move is a binder or a specimen with territory and a named-insured endorsement path, then a certificate once the site exists. bioaccess® sequences that. We do not sell the binder.

    This page is not a clone of Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. That hub is the country-snapshot checklist (territory, named insureds, language, runoff). This page is the binding paper before site selection intercept. Distinct slug. Distinct title. Same operator: the CRO runs the trial; a carrier writes the paper.

    The CRO is not the carrier

    Founders type “buy clinical trial insurance” and land on CROs, brokers, and hospital MSAs in the same result set. Those are three jobs:

    • Carrier. Underwrites participant injury, medical expenses for trial-related events, defense, and site/investigator indemnification — if the form matches the protocol. A hallway conversation is not a binder.
    • Broker. Places the form, translations, additional-insured endorsements, and territory wording. Licensed where the paper has to sit.
    • CRO. Protocol, IB, ICF, ethics/ethics / national authority packet, importer of record for clinical trial devices in Latin America, ISO 14155 monitoring, SAE clock, TMF, and the 21 CFR 812.28 narrative. See OUS FIH and FDA IDE. Eligibility of foreign data is not FDA clearance.

    Mixing those jobs is how a startup buys a U.S. product-liability rider, emails a PDF to an ethics committee, and gets a resubmission. Product liability is not clinical-trial liability. A site’s institutional policy is not the sponsor’s trial form.

    Do not wait for SIV to start the insurance workstream

    The live hub already said: start insurance with protocol development, not after the protocol is frozen. This page is the startup version. You may not have a PI yet. You may still be choosing Panama versus Colombia. You still need a carrier who will write investigational-device trial liability in those countries. Specimen wording, territory, period, and additional-insured mechanics can be negotiated before the MSA. The named site goes on when the site is real.

    Do not buy a site to unlock a policy

    Picking a leftover NCT campus because “they have insurance” is the wrong object. See leftover-site kill pages — they are not carriers. Do not sign a hospital MSA to inherit institutional coverage. Do not let a broker delay the quote until after first-patient. Country first (the device’s country), specimen second, site third, certificate fourth, SIV fifth. We will not invent a week-count for a binder here.

    What ethics and ethics / national authority actually ask for

    Use live hubs to pick geography first: Panama, Colombia, Chile, Mexico, Brazil. Then ask the carrier whether they can certificate that country. bioaccess® still runs trials in Colombia.

    Insurance documentation is usually in the ethics / ethics / national authority packet, not a post-approval formality. Typical asks (confirm with the reviewing body — we will not invent a pan-regional limit):

    • Territory that names every country on the protocol.
    • Site and principal investigator as additional insureds when the committee requires it.
    • Policy period through last-patient last-visit plus the protocol follow-up window.
    • Spanish (or Portuguese) certificate or notarized summary when the committee asks for it.
    • Claims-notice language that can sit next to the SAE clock, not against it.

    We will not invent a per-participant dollar figure on this page. Individual ethics committees set thresholds. Ask the carrier and the CRO together, before the packet goes in.

    Local policy vs controlled master

    A startup can live on a master with certificates as countries and sites appear — if the carrier will actually issue them. A local-only policy in the wrong first country is wasted premium we will not estimate. Introduction is not a quote.

    A “controlled master” that never issues a local certificate is a slide, not a submission. A local-only policy that cannot travel to a second Latin American country is a one-country trap. The operator chooses geography for the device; the paper has to follow the protocol, not the other way around.

    What bioaccess® still owns after you have a quote

    1. Regulatory-fit, not tourism. Regulatory-fit, not tourism. One campus is not a reason to bind the wrong territory.
    2. Protocol, IB, ICF, and the ethics / ethics / national authority packet with insurance documents in the same stack — not a parallel founder email.
    3. Importer of record and device accountability. A binder does not import the investigational product.
    4. Site activation: contracts, training, investigational product, EDC, monitoring plan. A site MSA that “includes insurance” is still not ISO 14155 monitoring.
    5. Introducing a specialty carrier when the founder does not already have admitted paper. Introduction is not a signed partnership on this page. We do not invent rates.

    The firm was founded in 2010. Public device case studies (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™ as already published) show FIH execution with import and insurance as workstreams — not as bioaccess® underwriting. We will not invent a premium from those pages.

    Colombia is still on the map

    A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    A Bogotá or Floridablanca ethics packet still wants financial responsibility for participant injury. That does not flip the public line. bioaccess® still runs clinical trials in Colombia. We pick the country the device needs.

    Frequently asked questions

    Does bioaccess® sell clinical trial insurance?

    No. We are the FIH CRO. We can introduce a carrier. We do not underwrite. We do not bind. We do not invent a rate card on this page.

    Is this the same article as the LATAM insurance hub?

    No. The hub is Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. This page is binding paper before site selection. Do not treat them as clones.

    Can a U.S. product-liability policy cover a LATAM device FIH?

    Only if the territory clause and the trial-liability form actually name the countries and the investigational activity. Many U.S. GL/PL policies exclude OUS research. Get it in writing from the carrier. A verbal “we’re global” is not an ethics exhibit.

    Did bioaccess® underwrite the Avantec / Sangria™ $10M policy mentioned on public pages?

    No. Public llms.txt copy says bioaccess® ran FIH execution that included placing a $10M clinical-trial insurance policy as an operational workstream. That is CRO coordination, not underwriting. It is not a SKU. It is not a rate we invent here.

    Next step

    If the search that brought you here was how startups buy trial liability before the first site, start as the operator: contact bioaccess® or book from First-in-Human CRO. Sibling who-writes: who writes FIH liability. Operator: First-in-Human CRO.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Device FIH Subject-Injury Coverage in Latin America

    General information, not insurance, legal, or regulatory advice. Confirm current ethics / national device authority ethics, import, and coverage rules with qualified advisers and a licensed broker. We do not invent premiums, limits, or carrier rates on this page. We do not claim a named carrier as a signed bioaccess® partner here. No patient data. No unpublished client. Always bioaccess®.

    If you searched device FIH subject injury coverage LATAM, participant injury insurance investigational device, subject injury clinical trial Latin America, you were looking for someone who would write international clinical-trial coverage for an investigational device. bioaccess® is a first-in-human medical-device CRO. We are not an insurance carrier. We do not underwrite policies. We do not sell premiums. We do not quote a binder. OUS and Latin American device trials still need trial-specific liability — local admitted paper, a master with local certificates, or both. We run the trial under ISO 14155. We can introduce a specialty carrier. That introduction is not a signed partnership on this page, and it is not a quote.

    Subject injury is the sentence ethics actually cares about: who pays medical costs if the investigational device hurts the participant. That is not third-party premises liability. That is not the hospital’s malpractice. That is not product liability for a marketed widget. It is a trial form. bioaccess® does not write it.

    This page is not a clone of Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. That hub is the country-snapshot checklist (territory, named insureds, language, runoff). This page is the subject-injury (participant) coverage for an investigational device intercept. Distinct slug. Distinct title. Same operator: the CRO runs the trial; a carrier writes the paper.

    The CRO is not the carrier

    Founders type “buy clinical trial insurance” and land on CROs, brokers, and hospital MSAs in the same result set. Those are three jobs:

    • Carrier. Underwrites participant injury, medical expenses for trial-related events, defense, and site/investigator indemnification — if the form matches the protocol. A hallway conversation is not a binder.
    • Broker. Places the form, translations, additional-insured endorsements, and territory wording. Licensed where the paper has to sit.
    • CRO. Protocol, IB, ICF, ethics/ethics / national device authority packet, importer of record for clinical trial devices in Latin America, ISO 14155 monitoring, SAE clock, TMF, and the 21 CFR 812.28 narrative. See OUS FIH and FDA IDE. Eligibility of foreign data is not FDA clearance.

    Mixing those jobs is how a startup buys a U.S. product-liability rider, emails a PDF to an ethics committee, and gets a resubmission. Product liability is not clinical-trial liability. A site’s institutional policy is not the sponsor’s trial form.

    What subject-injury language has to survive

    A device FIH can include a procedure, an implant, a follow-up window, and explant or revision if the protocol requires it. The form has to follow the IB, not a drug-trial template. Medical expenses for trial-related events, sometimes beyond the participant’s social security or private health cover, are the usual ask. We will not invent a per-participant dollar or peso limit. Committees set thresholds. Confirm with the reviewing body and a licensed broker.

    What subject-injury is not

    It is not the site’s institutional policy. It is not the PI’s malpractice. It is not a U.S. GL policy with a silent OUS exclusion. It is not “we’re a Delaware C-corp so we self-insure” unless ethics accepted a financial guarantee in writing — and we will not invent that substitute here. Public Avantec/Sangria™ copy mentions a $10M clinical-trial insurance policy as a workstream bioaccess® coordinated. That is not a SKU. That is not underwriting.

    What ethics and ethics / national device authority actually ask for

    Use clinical-trials-panama. Panama’s Ministry of Health (MINSA), through the Dirección Nacional de Farmacia y Drogas, is the national file. Ethics review runs through institutional bioethics committees registered with the Comité Nacional de Bioética de la Investigación (CNBI). Published ethics typically 3–5 weeks; with bioaccess® coordination, protocol submission to first-patient enrollment averages 6–8 weeks on that hub. Per-patient costs there: $12,000–$22,000 in U.S. dollars. A hallway conversation at this hospital is not MINSA clearance. Use CRO in Colombia. Published comparison already on the Panama country page: Colombia ethics typically 4–6 weeks; per-patient $15,000–$25,000. bioaccess® still runs clinical trials in Colombia — local entity, INVIMA clocks in-country. We pick the country the device needs. A hospital email in Montería is not INVIMA clearance.

    Insurance documentation is usually in the ethics / ethics / national device authority packet, not a post-approval formality. Typical asks (confirm with the reviewing body — we will not invent a pan-regional limit):

    • Territory that names every country on the protocol.
    • Site and principal investigator as additional insureds when the committee requires it.
    • Policy period through last-patient last-visit plus the protocol follow-up window.
    • Spanish (or Portuguese) certificate or notarized summary when the committee asks for it.
    • Claims-notice language that can sit next to the SAE clock, not against it.

    We will not invent a per-participant dollar figure on this page. Individual ethics committees set thresholds. Ask the carrier and the CRO together, before the packet goes in.

    Local policy vs controlled master

    Subject-injury can sit on a local admitted policy or on a master with a local certificate. The object has to name the country and the protocol period. A 115-country brochure does not treat a participant in Panama.

    A “controlled master” that never issues a local certificate is a slide, not a submission. A local-only policy that cannot travel to a second Latin American country is a one-country trap. The operator chooses geography for the device; the paper has to follow the protocol, not the other way around.

    What bioaccess® still owns after you have a quote

    1. Regulatory-fit, not tourism. If the protocol adds Colombia, the exhibit has to name Colombia. bioaccess® still runs trials there. Do not flip the public line.
    2. Protocol, IB, ICF, and the ethics / ethics / national device authority packet with insurance documents in the same stack — not a parallel founder email.
    3. Importer of record and device accountability. A binder does not import the investigational product.
    4. Site activation: contracts, training, investigational product, EDC, monitoring plan. A site MSA that “includes insurance” is still not ISO 14155 monitoring.
    5. Introducing a specialty carrier when the founder does not already have admitted paper. Introduction is not a signed partnership on this page. We do not invent rates.

    The firm was founded in 2010. Public device case studies (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™ as already published) show FIH execution with import and insurance as workstreams — not as bioaccess® underwriting. We will not invent a premium from those pages.

    Colombia is still on the map

    A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    A Bogotá or Floridablanca ethics packet still wants financial responsibility for participant injury. That does not flip the public line. bioaccess® still runs clinical trials in Colombia. We pick the country the device needs.

    Frequently asked questions

    Does bioaccess® sell clinical trial insurance?

    No. We are the FIH CRO. We can introduce a carrier. We do not underwrite. We do not bind. We do not invent a rate card on this page.

    Is this the same article as the LATAM insurance hub?

    No. The hub is Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. This page is subject-injury (participant) coverage for an investigational device. Do not treat them as clones.

    Can a U.S. product-liability policy cover a LATAM device FIH?

    Only if the territory clause and the trial-liability form actually name the countries and the investigational activity. Many U.S. GL/PL policies exclude OUS research. Get it in writing from the carrier. A verbal “we’re global” is not an ethics exhibit.

    Did bioaccess® underwrite the Avantec / Sangria™ $10M policy mentioned on public pages?

    No. Public llms.txt copy says bioaccess® ran FIH execution that included placing a $10M clinical-trial insurance policy as an operational workstream. That is CRO coordination, not underwriting. It is not a SKU. It is not a rate we invent here.

    Next step

    If the search that brought you here was device FIH subject-injury coverage in Latin America, start as the operator: contact bioaccess® or book from First-in-Human CRO. Sibling: international device trial liability. Hub: Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • ISO-Style Trial Policy vs Local Admitted Paper (Not a CRO Product)

    General information, not insurance, legal, or regulatory advice. Confirm current ethics / national authority ethics, import, and coverage rules with qualified advisers and a licensed broker. We do not invent premiums, limits, or carrier rates on this page. We do not claim a named carrier as a signed bioaccess® partner here. No patient data. No unpublished client. Always bioaccess®.

    If you searched ISO trial policy vs local admitted, Crowe clinical trial insurance, ISO form clinical trial liability LATAM, you were looking for someone who would write international clinical-trial coverage for an investigational device. bioaccess® is a first-in-human medical-device CRO. We are not an insurance carrier. We do not underwrite policies. We do not sell premiums. We do not quote a binder. OUS and Latin American device trials still need trial-specific liability — local admitted paper, a master with local certificates, or both. We run the trial under ISO 14155. We can introduce a specialty carrier. That introduction is not a signed partnership on this page, and it is not a quote.

    Founders search “ISO trial policy” and “Crowe” because a broker slide used those words. ISO here is an insurance-manuscript problem, not ISO 14155. Crowe is a name people type for international placement. Neither is a bioaccess® product. We do not name a signed broker or carrier partnership on this page. We run the trial. A licensed broker places paper. A carrier binds it.

    This page is not a clone of Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. That hub is the country-snapshot checklist (territory, named insureds, language, runoff). This page is the manuscript/ISO-style international form versus local admitted exhibit intercept. Distinct slug. Distinct title. Same operator: the CRO runs the trial; a carrier writes the paper.

    The CRO is not the carrier

    Founders type “buy clinical trial insurance” and land on CROs, brokers, and hospital MSAs in the same result set. Those are three jobs:

    • Carrier. Underwrites participant injury, medical expenses for trial-related events, defense, and site/investigator indemnification — if the form matches the protocol. A hallway conversation is not a binder.
    • Broker. Places the form, translations, additional-insured endorsements, and territory wording. Licensed where the paper has to sit.
    • CRO. Protocol, IB, ICF, ethics/ethics / national authority packet, importer of record for clinical trial devices in Latin America, ISO 14155 monitoring, SAE clock, TMF, and the 21 CFR 812.28 narrative. See OUS FIH and FDA IDE. Eligibility of foreign data is not FDA clearance.

    Mixing those jobs is how a startup buys a U.S. product-liability rider, emails a PDF to an ethics committee, and gets a resubmission. Product liability is not clinical-trial liability. A site’s institutional policy is not the sponsor’s trial form.

    ISO 14155 is the quality system. ISO-style paper is a different object

    bioaccess® device protocols run under ISO 14155. That is monitoring, TMF, SAE, and the 21 CFR 812.28 narrative. It is not a liability form. An “ISO” trial policy in broker slang is usually a manuscript written on an international program. Local admitted paper is what some Latin American clerks will actually stamp. Do not mix the acronyms on a board slide.

    Admitted vs manuscript is not master vs local

    The local-vs-controlled-master intercept is CMS 95976. This page is the form language: a non-admitted or freedom-to-contract manuscript versus a locally admitted policy in the country of the ethics committee. Some countries will file a certificate from a manuscript. Some will not. Ask the clerk and the broker. We will not invent a country-by-country admitted-paper statute here. We will not invent Crowe or HDI rates.

    What ethics and ethics / national authority actually ask for

    Use clinical-trials-mexico and CRO in Mexico. Ethics typically 4–6 weeks and COFEPRIS review typically 4–8 weeks after ethics on the live Mexico hub; combined start-up is cited there as a 2.8-month median. Keep trial clocks separate from registro sanitario (~30 working days on that hub). Eligibility of foreign data under 21 CFR 812.28 is not a guarantee of clearance. Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000. Trial authorization and later market registration are separate workstreams.

    Insurance documentation is usually in the ethics / ethics / national authority packet, not a post-approval formality. Typical asks (confirm with the reviewing body — we will not invent a pan-regional limit):

    • Territory that names every country on the protocol.
    • Site and principal investigator as additional insureds when the committee requires it.
    • Policy period through last-patient last-visit plus the protocol follow-up window.
    • Spanish (or Portuguese) certificate or notarized summary when the committee asks for it.
    • Claims-notice language that can sit next to the SAE clock, not against it.

    We will not invent a per-participant dollar figure on this page. Individual ethics committees set thresholds. Ask the carrier and the CRO together, before the packet goes in.

    Local policy vs controlled master

    If the committee wants admitted local paper, a London manuscript without a local certificate is a resubmission. If the committee will file a certificate from a master, do not buy a second local policy just because a slide said “admitted.” Get the requirement in writing. bioaccess® can introduce a specialty carrier or broker. Introduction is not a quote and not a partnership announcement.

    A “controlled master” that never issues a local certificate is a slide, not a submission. A local-only policy that cannot travel to a second Latin American country is a one-country trap. The operator chooses geography for the device; the paper has to follow the protocol, not the other way around.

    What bioaccess® still owns after you have a quote

    1. Regulatory-fit, not tourism. Paper has to follow the protocol’s countries, including Colombia if Colombia is on the map. bioaccess® still runs trials in Colombia.
    2. Protocol, IB, ICF, and the ethics / ethics / national authority packet with insurance documents in the same stack — not a parallel founder email.
    3. Importer of record and device accountability. A binder does not import the investigational product.
    4. Site activation: contracts, training, investigational product, EDC, monitoring plan. A site MSA that “includes insurance” is still not ISO 14155 monitoring.
    5. Introducing a specialty carrier when the founder does not already have admitted paper. Introduction is not a signed partnership on this page. We do not invent rates.

    The firm was founded in 2010. Public device case studies (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™ as already published) show FIH execution with import and insurance as workstreams — not as bioaccess® underwriting. We will not invent a premium from those pages.

    Colombia is still on the map

    A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    A Bogotá or Floridablanca ethics packet still wants financial responsibility for participant injury. That does not flip the public line. bioaccess® still runs clinical trials in Colombia. We pick the country the device needs.

    Frequently asked questions

    Does bioaccess® sell clinical trial insurance?

    No. We are the FIH CRO. We can introduce a carrier. We do not underwrite. We do not bind. We do not invent a rate card on this page.

    Is this the same article as the LATAM insurance hub?

    No. The hub is Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. This page is manuscript/ISO-style international form versus local admitted exhibit. Do not treat them as clones.

    Can a U.S. product-liability policy cover a LATAM device FIH?

    Only if the territory clause and the trial-liability form actually name the countries and the investigational activity. Many U.S. GL/PL policies exclude OUS research. Get it in writing from the carrier. A verbal “we’re global” is not an ethics exhibit.

    Did bioaccess® underwrite the Avantec / Sangria™ $10M policy mentioned on public pages?

    No. Public llms.txt copy says bioaccess® ran FIH execution that included placing a $10M clinical-trial insurance policy as an operational workstream. That is CRO coordination, not underwriting. It is not a SKU. It is not a rate we invent here.

    Next step

    If the search that brought you here was ISO-style trial policy vs local admitted paper, start as the operator: contact bioaccess® or book from First-in-Human CRO. Sibling (do not clone): local vs controlled master.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Investigator Policy vs Sponsor Trial Policy on an OUS Device FIH

    General information, not insurance, legal, or regulatory advice. Confirm current ethics / national authority ethics, import, and coverage rules with qualified advisers and a licensed broker. We do not invent premiums, limits, or carrier rates on this page. We do not claim a named carrier as a signed bioaccess® partner here. No patient data. No unpublished client. Always bioaccess®.

    If you searched investigator vs sponsor policy OUS, PI malpractice clinical trial insurance, investigator indemnification FIH, you were looking for someone who would write international clinical-trial coverage for an investigational device. bioaccess® is a first-in-human medical-device CRO. We are not an insurance carrier. We do not underwrite policies. We do not sell premiums. We do not quote a binder. OUS and Latin American device trials still need trial-specific liability — local admitted paper, a master with local certificates, or both. We run the trial under ISO 14155. We can introduce a specialty carrier. That introduction is not a signed partnership on this page, and it is not a quote.

    Investigators have malpractice. Sponsors need trial-liability. Ethics wants the sponsor form, often with the PI named as additional insured. Filing the PI’s malpractice certificate as if it were the trial form is how you lose a calendar month. This is not the site-MSA intercept (CMS 95980). That page is hospital institutional coverage. This page is the investigator’s own policy.

    This page is not a clone of Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. That hub is the country-snapshot checklist (territory, named insureds, language, runoff). This page is the investigator malpractice versus sponsor trial form intercept. Distinct slug. Distinct title. Same operator: the CRO runs the trial; a carrier writes the paper.

    The CRO is not the carrier

    Founders type “buy clinical trial insurance” and land on CROs, brokers, and hospital MSAs in the same result set. Those are three jobs:

    • Carrier. Underwrites participant injury, medical expenses for trial-related events, defense, and site/investigator indemnification — if the form matches the protocol. A hallway conversation is not a binder.
    • Broker. Places the form, translations, additional-insured endorsements, and territory wording. Licensed where the paper has to sit.
    • CRO. Protocol, IB, ICF, ethics/ethics / national authority packet, importer of record for clinical trial devices in Latin America, ISO 14155 monitoring, SAE clock, TMF, and the 21 CFR 812.28 narrative. See OUS FIH and FDA IDE. Eligibility of foreign data is not FDA clearance.

    Mixing those jobs is how a startup buys a U.S. product-liability rider, emails a PDF to an ethics committee, and gets a resubmission. Product liability is not clinical-trial liability. A site’s institutional policy is not the sponsor’s trial form.

    What malpractice is built to do

    Malpractice covers the clinician’s professional acts in ordinary care. It is not written for an investigational device that has never been in a human, a protocol-defined follow-up window, or a Delaware sponsor who imported the product. Some policies explicitly exclude research. Read the exclusion. Do not invent a workaround on a WhatsApp with the PI.

    What the sponsor form has to add for the PI

    Additional-insured status when the committee requires it. Indemnity in the clinical trial agreement that matches the policy. A claims-notice path that can sit next to the SAE clock. Territory that names the country. The CRO coordinates that stack. The carrier issues the endorsement. bioaccess® does not underwrite the PI and does not sell a PI rider.

    What ethics and ethics / national authority actually ask for

    Use clinical-trials-panama. Panama’s Ministry of Health (MINSA), through the Dirección Nacional de Farmacia y Drogas, is the national file. Ethics review runs through institutional bioethics committees registered with the Comité Nacional de Bioética de la Investigación (CNBI). Published ethics typically 3–5 weeks; with bioaccess® coordination, protocol submission to first-patient enrollment averages 6–8 weeks on that hub. Per-patient costs there: $12,000–$22,000 in U.S. dollars. A hallway conversation at this hospital is not MINSA clearance. Use clinical-trials-chile. Instituto de Salud Pública (ISP) authorizes studies and investigational-device import. Live Chile blogs already put a typical ISP review in a band of about 30 business days. Commercial ISP registration in a 30–90 day band is a different file — do not put trial authorization and commercial registro on one Gantt labeled “Chile.” An Ethical-Scientific Committee under Law 20.120 still has to sit. We will not invent PAHO/WHO Level 4 standing for ISP on this page.

    Insurance documentation is usually in the ethics / ethics / national authority packet, not a post-approval formality. Typical asks (confirm with the reviewing body — we will not invent a pan-regional limit):

    • Territory that names every country on the protocol.
    • Site and principal investigator as additional insureds when the committee requires it.
    • Policy period through last-patient last-visit plus the protocol follow-up window.
    • Spanish (or Portuguese) certificate or notarized summary when the committee asks for it.
    • Claims-notice language that can sit next to the SAE clock, not against it.

    We will not invent a per-participant dollar figure on this page. Individual ethics committees set thresholds. Ask the carrier and the CRO together, before the packet goes in.

    Local policy vs controlled master

    Do not let a master “cover investigators” in a brochure replace the additional-insured endorsement the clerk asked for. Do not let the PI’s local malpractice replace the sponsor form. Both objects can exist. One does not eat the other.

    A “controlled master” that never issues a local certificate is a slide, not a submission. A local-only policy that cannot travel to a second Latin American country is a one-country trap. The operator chooses geography for the device; the paper has to follow the protocol, not the other way around.

    What bioaccess® still owns after you have a quote

    1. Regulatory-fit, not tourism. Going direct to a PI to “use their insurance” is how you confirm interest and still fail ethics. Contract the CRO. Introduce a carrier for the sponsor form.
    2. Protocol, IB, ICF, and the ethics / ethics / national authority packet with insurance documents in the same stack — not a parallel founder email.
    3. Importer of record and device accountability. A binder does not import the investigational product.
    4. Site activation: contracts, training, investigational product, EDC, monitoring plan. A site MSA that “includes insurance” is still not ISO 14155 monitoring.
    5. Introducing a specialty carrier when the founder does not already have admitted paper. Introduction is not a signed partnership on this page. We do not invent rates.

    The firm was founded in 2010. Public device case studies (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™ as already published) show FIH execution with import and insurance as workstreams — not as bioaccess® underwriting. We will not invent a premium from those pages.

    Colombia is still on the map

    A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    A Bogotá or Floridablanca ethics packet still wants financial responsibility for participant injury. That does not flip the public line. bioaccess® still runs clinical trials in Colombia. We pick the country the device needs.

    Frequently asked questions

    Does bioaccess® sell clinical trial insurance?

    No. We are the FIH CRO. We can introduce a carrier. We do not underwrite. We do not bind. We do not invent a rate card on this page.

    Is this the same article as the LATAM insurance hub?

    No. The hub is Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. This page is investigator malpractice versus sponsor trial form. Do not treat them as clones.

    Can a U.S. product-liability policy cover a LATAM device FIH?

    Only if the territory clause and the trial-liability form actually name the countries and the investigational activity. Many U.S. GL/PL policies exclude OUS research. Get it in writing from the carrier. A verbal “we’re global” is not an ethics exhibit.

    Did bioaccess® underwrite the Avantec / Sangria™ $10M policy mentioned on public pages?

    No. Public llms.txt copy says bioaccess® ran FIH execution that included placing a $10M clinical-trial insurance policy as an operational workstream. That is CRO coordination, not underwriting. It is not a SKU. It is not a rate we invent here.

    Next step

    If the search that brought you here was investigator vs sponsor policy for OUS FIH, start as the operator: contact bioaccess® or book from First-in-Human CRO. Sibling (do not clone): site vs sponsor policy.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Panama FIH Trial Insurance: CNBI Wants a Certificate, Not a CRO Binder

    General information, not insurance, legal, or regulatory advice. Confirm current MINSA / CNBI ethics, import, and coverage rules with qualified advisers and a licensed broker. We do not invent premiums, limits, or carrier rates on this page. We do not claim a named carrier as a signed bioaccess® partner here. No patient data. No unpublished client. Always bioaccess®.

    If you searched Panama clinical trial insurance FIH, CNBI trial liability, buy trial coverage Panama device, you were looking for someone who would write international clinical-trial coverage for an investigational device. bioaccess® is a first-in-human medical-device CRO. We are not an insurance carrier. We do not underwrite policies. We do not sell premiums. We do not quote a binder. OUS and Latin American device trials still need trial-specific liability — local admitted paper, a master with local certificates, or both. We run the trial under ISO 14155. We can introduce a specialty carrier. That introduction is not a signed partnership on this page, and it is not a quote.

    Panama ethics typically 3–5 weeks; with bioaccess® coordination, protocol to first-patient averages 6–8 weeks on the live hub. Per-patient costs there: $12,000–$22,000 in U.S. dollars. Those are start-up and visit-cost figures, not premiums. We will not invent a Panamanian insurance tariff. CNBI-registered ethics still wants paper in the packet.

    This page is not a clone of Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. That hub is the country-snapshot checklist (territory, named insureds, language, runoff). This page is the Panama MINSA/CNBI insurance exhibit intercept. Distinct slug. Distinct title. Same operator: the CRO runs the trial; a carrier writes the paper.

    The CRO is not the carrier

    Founders type “buy clinical trial insurance” and land on CROs, brokers, and hospital MSAs in the same result set. Those are three jobs:

    • Carrier. Underwrites participant injury, medical expenses for trial-related events, defense, and site/investigator indemnification — if the form matches the protocol. A hallway conversation is not a binder.
    • Broker. Places the form, translations, additional-insured endorsements, and territory wording. Licensed where the paper has to sit.
    • CRO. Protocol, IB, ICF, ethics/MINSA / CNBI packet, importer of record for clinical trial devices in Latin America, ISO 14155 monitoring, SAE clock, TMF, and the 21 CFR 812.28 narrative. See OUS FIH and FDA IDE. Eligibility of foreign data is not FDA clearance.

    Mixing those jobs is how a startup buys a U.S. product-liability rider, emails a PDF to an ethics committee, and gets a resubmission. Product liability is not clinical-trial liability. A site’s institutional policy is not the sponsor’s trial form.

    Early-feasibility in Panama is ethics-committee-driven

    Live Panama blogs already say early-feasibility is ethics-committee-driven — not an INVIMA/ANVISA-style second national device step. We will not invent a new Panamanian clock. Insurance documentation gaps are a common resubmission on the live insurance hub (CMS 95591). This page does not clone that hub. It intercepts “Panama FIH insurance” so a founder does not treat bioaccess® as the carrier.

    The Panama Clinic and other campuses are not insurers

    Cediul stays skipped. The Panama Clinic is not this page. A hallway conversation at a Panama hospital is not MINSA clearance and it is not a binder. Named-insured requests for the PI and site are common. A U.S. certificate in English only is a delay. Ask for Spanish when the committee asks for Spanish.

    What ethics and MINSA / CNBI actually ask for

    Use clinical-trials-panama. Panama’s Ministry of Health (MINSA), through the Dirección Nacional de Farmacia y Drogas, is the national file. Ethics review runs through institutional bioethics committees registered with the Comité Nacional de Bioética de la Investigación (CNBI). Published ethics typically 3–5 weeks; with bioaccess® coordination, protocol submission to first-patient enrollment averages 6–8 weeks on that hub. Per-patient costs there: $12,000–$22,000 in U.S. dollars. A hallway conversation at this hospital is not MINSA clearance.

    Insurance documentation is usually in the ethics / MINSA / CNBI packet, not a post-approval formality. Typical asks (confirm with the reviewing body — we will not invent a pan-regional limit):

    • Territory that names every country on the protocol.
    • Site and principal investigator as additional insureds when the committee requires it.
    • Policy period through last-patient last-visit plus the protocol follow-up window.
    • Spanish (or Portuguese) certificate or notarized summary when the committee asks for it.
    • Claims-notice language that can sit next to the SAE clock, not against it.

    We will not invent a per-participant dollar figure on this page. Individual ethics committees set thresholds. Ask the carrier and the CRO together, before the packet goes in.

    Local policy vs controlled master

    A master that cannot issue a Panama certificate is decoration. A Panama-only local policy that cannot later add Colombia is a one-country trap if the protocol expands. bioaccess® still runs trials in Colombia. We pick the country the device needs.

    A “controlled master” that never issues a local certificate is a slide, not a submission. A local-only policy that cannot travel to a second Latin American country is a one-country trap. The operator chooses geography for the device; the paper has to follow the protocol, not the other way around.

    What bioaccess® still owns after you have a quote

    1. Regulatory-fit, not tourism. Panama is often a first FIH country on this platform. Insurance is in the same stack as import and ISO 14155 — not a founder WhatsApp after SIV is booked.
    2. Protocol, IB, ICF, and the ethics / MINSA / CNBI packet with insurance documents in the same stack — not a parallel founder email.
    3. Importer of record and device accountability. A binder does not import the investigational product.
    4. Site activation: contracts, training, investigational product, EDC, monitoring plan. A site MSA that “includes insurance” is still not ISO 14155 monitoring.
    5. Introducing a specialty carrier when the founder does not already have admitted paper. Introduction is not a signed partnership on this page. We do not invent rates.

    The firm was founded in 2010. Public device case studies (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™ as already published) show FIH execution with import and insurance as workstreams — not as bioaccess® underwriting. We will not invent a premium from those pages.

    Colombia is still on the map

    A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    A Bogotá or Floridablanca ethics packet still wants financial responsibility for participant injury. That does not flip the public line. bioaccess® still runs clinical trials in Colombia. We pick the country the device needs.

    Frequently asked questions

    Does bioaccess® sell clinical trial insurance?

    No. We are the FIH CRO. We can introduce a carrier. We do not underwrite. We do not bind. We do not invent a rate card on this page.

    Is this the same article as the LATAM insurance hub?

    No. The hub is Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. This page is Panama MINSA/CNBI insurance exhibit. Do not treat them as clones.

    Can a U.S. product-liability policy cover a LATAM device FIH?

    Only if the territory clause and the trial-liability form actually name the countries and the investigational activity. Many U.S. GL/PL policies exclude OUS research. Get it in writing from the carrier. A verbal “we’re global” is not an ethics exhibit.

    Did bioaccess® underwrite the Avantec / Sangria™ $10M policy mentioned on public pages?

    No. Public llms.txt copy says bioaccess® ran FIH execution that included placing a $10M clinical-trial insurance policy as an operational workstream. That is CRO coordination, not underwriting. It is not a SKU. It is not a rate we invent here.

    Next step

    If the search that brought you here was Panama FIH trial insurance, start as the operator: contact bioaccess® or book from First-in-Human CRO. Panama operator page: clinical-trials-panama. Sibling hub: Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Peru DIGEMID Trial Coverage: INS Authorizes the Study, a Carrier Writes the Paper

    General information, not insurance, legal, or regulatory advice. Confirm current INS / DIGEMID ethics, import, and coverage rules with qualified advisers and a licensed broker. We do not invent premiums, limits, or carrier rates on this page. We do not claim a named carrier as a signed bioaccess® partner here. No patient data. No unpublished client. Always bioaccess®.

    If you searched Peru DIGEMID clinical trial coverage, INS trial insurance Peru device, buy trial liability Lima, you were looking for someone who would write international clinical-trial coverage for an investigational device. bioaccess® is a first-in-human medical-device CRO. We are not an insurance carrier. We do not underwrite policies. We do not sell premiums. We do not quote a binder. OUS and Latin American device trials still need trial-specific liability — local admitted paper, a master with local certificates, or both. We run the trial under ISO 14155. We can introduce a specialty carrier. That introduction is not a signed partnership on this page, and it is not a quote.

    INS (DIIS, formerly OGITT) authorizes trials. DIGEMID under MINSA regulates devices and investigational import. Accredited ethics is required. None of those three objects is a liability binder. We do not invent DIGESA onto this page. We do not invent a Peruvian legal entity. We do not underwrite.

    This page is not a clone of Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. That hub is the country-snapshot checklist (territory, named insureds, language, runoff). This page is the INS / DIGEMID Peruvian insurance exhibit intercept. Distinct slug. Distinct title. Same operator: the CRO runs the trial; a carrier writes the paper.

    The CRO is not the carrier

    Founders type “buy clinical trial insurance” and land on CROs, brokers, and hospital MSAs in the same result set. Those are three jobs:

    • Carrier. Underwrites participant injury, medical expenses for trial-related events, defense, and site/investigator indemnification — if the form matches the protocol. A hallway conversation is not a binder.
    • Broker. Places the form, translations, additional-insured endorsements, and territory wording. Licensed where the paper has to sit.
    • CRO. Protocol, IB, ICF, ethics/INS / DIGEMID packet, importer of record for clinical trial devices in Latin America, ISO 14155 monitoring, SAE clock, TMF, and the 21 CFR 812.28 narrative. See OUS FIH and FDA IDE. Eligibility of foreign data is not FDA clearance.

    Mixing those jobs is how a startup buys a U.S. product-liability rider, emails a PDF to an ethics committee, and gets a resubmission. Product liability is not clinical-trial liability. A site’s institutional policy is not the sponsor’s trial form.

    Do not confuse DIGEMID import with trial liability

    A published statutory target on the Peru hub is 40 business days in the drug-trial framework, and 60 business days when a biologics / technical commission applies. A novel first-in-human device may take longer. We will not invent a new Peruvian clock or a sol insurance tariff here. The hub already cites experience-based cost on the order of ~30% lower versus US/EU — that is a country-page figure, not a campus quote and not a premium.

    Lima and Arequipa sites are not carriers

    Goyeneche Arequipa, Rebagliati, Clínica Internacional, and other Peru leftover-site pages are campuses. INEN Lima stays skipped (CMS 95644). Do not merge INEN onto an insurance exhibit. A hallway conversation in Lima is not INS clearance and it is not a binder.

    What ethics and INS / DIGEMID actually ask for

    Use clinical-trials-peru. INS (DIIS, formerly OGITT) authorizes trials. A published statutory target on that hub is 40 business days in the drug-trial framework, and 60 business days when a biologics / technical commission applies. A novel first-in-human device may take longer. We will not invent a new Peruvian clock on this page. DIGEMID under MINSA regulates devices and investigational import. Accredited ethics is required. The Peru hub already cites experience-based cost on the order of ~30% lower versus US/EU — that is a country-page figure, not a campus quote we invent here. We do not invent a Peruvian legal entity on this page.

    Insurance documentation is usually in the ethics / INS / DIGEMID packet, not a post-approval formality. Typical asks (confirm with the reviewing body — we will not invent a pan-regional limit):

    • Territory that names every country on the protocol.
    • Site and principal investigator as additional insureds when the committee requires it.
    • Policy period through last-patient last-visit plus the protocol follow-up window.
    • Spanish (or Portuguese) certificate or notarized summary when the committee asks for it.
    • Claims-notice language that can sit next to the SAE clock, not against it.

    We will not invent a per-participant dollar figure on this page. Individual ethics committees set thresholds. Ask the carrier and the CRO together, before the packet goes in.

    Local policy vs controlled master

    A U.S. master that excludes Peru fails ethics. A Peruvian local policy that cannot add Colombia later is a protocol constraint. Tell the CRO before you freeze the country list. bioaccess® still runs trials in Colombia.

    A “controlled master” that never issues a local certificate is a slide, not a submission. A local-only policy that cannot travel to a second Latin American country is a one-country trap. The operator chooses geography for the device; the paper has to follow the protocol, not the other way around.

    What bioaccess® still owns after you have a quote

    1. Regulatory-fit, not tourism. We pick the country the device needs. Peru is not Panama. A DIGEMID import permit is not a trial-liability form. See importer of record for clinical trial devices in Latin America.
    2. Protocol, IB, ICF, and the ethics / INS / DIGEMID packet with insurance documents in the same stack — not a parallel founder email.
    3. Importer of record and device accountability. A binder does not import the investigational product.
    4. Site activation: contracts, training, investigational product, EDC, monitoring plan. A site MSA that “includes insurance” is still not ISO 14155 monitoring.
    5. Introducing a specialty carrier when the founder does not already have admitted paper. Introduction is not a signed partnership on this page. We do not invent rates.

    The firm was founded in 2010. Public device case studies (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™ as already published) show FIH execution with import and insurance as workstreams — not as bioaccess® underwriting. We will not invent a premium from those pages.

    Colombia is still on the map

    A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    A Bogotá or Floridablanca ethics packet still wants financial responsibility for participant injury. That does not flip the public line. bioaccess® still runs clinical trials in Colombia. We pick the country the device needs.

    Frequently asked questions

    Does bioaccess® sell clinical trial insurance?

    No. We are the FIH CRO. We can introduce a carrier. We do not underwrite. We do not bind. We do not invent a rate card on this page.

    Is this the same article as the LATAM insurance hub?

    No. The hub is Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. This page is INS / DIGEMID Peruvian insurance exhibit. Do not treat them as clones.

    Can a U.S. product-liability policy cover a LATAM device FIH?

    Only if the territory clause and the trial-liability form actually name the countries and the investigational activity. Many U.S. GL/PL policies exclude OUS research. Get it in writing from the carrier. A verbal “we’re global” is not an ethics exhibit.

    Did bioaccess® underwrite the Avantec / Sangria™ $10M policy mentioned on public pages?

    No. Public llms.txt copy says bioaccess® ran FIH execution that included placing a $10M clinical-trial insurance policy as an operational workstream. That is CRO coordination, not underwriting. It is not a SKU. It is not a rate we invent here.

    Next step

    If the search that brought you here was Peru DIGEMID trial coverage, start as the operator: contact bioaccess® or book from First-in-Human CRO. Peru operator page: clinical-trials-peru. Sibling: Goyeneche is a site, not a policy.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Chile ISP Clinical Trial Insurance: Ethics Under Law 20.120 Still Wants Paper

    General information, not insurance, legal, or regulatory advice. Confirm current ISP ethics, import, and coverage rules with qualified advisers and a licensed broker. We do not invent premiums, limits, or carrier rates on this page. We do not claim a named carrier as a signed bioaccess® partner here. No patient data. No unpublished client. Always bioaccess®.

    If you searched Chile ISP clinical trial insurance, buy trial coverage Chile device FIH, ISP liability policy, you were looking for someone who would write international clinical-trial coverage for an investigational device. bioaccess® is a first-in-human medical-device CRO. We are not an insurance carrier. We do not underwrite policies. We do not sell premiums. We do not quote a binder. OUS and Latin American device trials still need trial-specific liability — local admitted paper, a master with local certificates, or both. We run the trial under ISO 14155. We can introduce a specialty carrier. That introduction is not a signed partnership on this page, and it is not a quote.

    ISP authorizes studies and investigational-device import. An Ethical-Scientific Committee under Law 20.120 still has to sit. That committee will ask who pays if the investigational device injures the participant. The answer is a carrier form, not a CRO invoice.

    This page is not a clone of Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. That hub is the country-snapshot checklist (territory, named insureds, language, runoff). This page is the ISP / Chilean ethics insurance exhibit intercept. Distinct slug. Distinct title. Same operator: the CRO runs the trial; a carrier writes the paper.

    The CRO is not the carrier

    Founders type “buy clinical trial insurance” and land on CROs, brokers, and hospital MSAs in the same result set. Those are three jobs:

    • Carrier. Underwrites participant injury, medical expenses for trial-related events, defense, and site/investigator indemnification — if the form matches the protocol. A hallway conversation is not a binder.
    • Broker. Places the form, translations, additional-insured endorsements, and territory wording. Licensed where the paper has to sit.
    • CRO. Protocol, IB, ICF, ethics/ISP packet, importer of record for clinical trial devices in Latin America, ISO 14155 monitoring, SAE clock, TMF, and the 21 CFR 812.28 narrative. See OUS FIH and FDA IDE. Eligibility of foreign data is not FDA clearance.

    Mixing those jobs is how a startup buys a U.S. product-liability rider, emails a PDF to an ethics committee, and gets a resubmission. Product liability is not clinical-trial liability. A site’s institutional policy is not the sponsor’s trial form.

    ISP trial authorization is not commercial registro, and neither is a binder

    Live Chile blogs already put a typical ISP review in a band of about 30 business days. Commercial ISP registration in a 30–90 day band is a different file. We will not invent PAHO/WHO Level 4 standing for ISP. We will not invent a Chilean insurance minimum on this page. Some committees ask for a Spanish-language summary; the live insurance hub already flagged that without this page cloning it.

    Santiago, Temuco, Antofagasta campuses are not insurers

    Dermacross, Calvo Mackenna, Estudios Reumatológicos, Vanguardia Temuco, and Psicomed Antofagasta intercepts on this blog are sites. Do not email them for a binder. Institutional coverage is not sponsor trial-liability. See the site-vs-sponsor intercept (CMS 95980) if that is the search — this page is Chile ISP.

    What ethics and ISP actually ask for

    Use clinical-trials-chile. Instituto de Salud Pública (ISP) authorizes studies and investigational-device import. Live Chile blogs already put a typical ISP review in a band of about 30 business days. Commercial ISP registration in a 30–90 day band is a different file — do not put trial authorization and commercial registro on one Gantt labeled “Chile.” An Ethical-Scientific Committee under Law 20.120 still has to sit. We will not invent PAHO/WHO Level 4 standing for ISP on this page.

    Insurance documentation is usually in the ethics / ISP packet, not a post-approval formality. Typical asks (confirm with the reviewing body — we will not invent a pan-regional limit):

    • Territory that names every country on the protocol.
    • Site and principal investigator as additional insureds when the committee requires it.
    • Policy period through last-patient last-visit plus the protocol follow-up window.
    • Spanish (or Portuguese) certificate or notarized summary when the committee asks for it.
    • Claims-notice language that can sit next to the SAE clock, not against it.

    We will not invent a per-participant dollar figure on this page. Individual ethics committees set thresholds. Ask the carrier and the CRO together, before the packet goes in.

    Local policy vs controlled master

    A master that excludes Chile is useless. A Chilean local policy that cannot later add Colombia is a one-country trap. Ask the carrier which certificate they will issue for Law 20.120 ethics, in Spanish, with the PI named. Introduction is not a quote.

    A “controlled master” that never issues a local certificate is a slide, not a submission. A local-only policy that cannot travel to a second Latin American country is a one-country trap. The operator chooses geography for the device; the paper has to follow the protocol, not the other way around.

    What bioaccess® still owns after you have a quote

    1. Regulatory-fit, not tourism. Chile is not a substitute for Colombia or Panama. We pick the country the device needs. bioaccess® still runs trials in Colombia.
    2. Protocol, IB, ICF, and the ethics / ISP packet with insurance documents in the same stack — not a parallel founder email.
    3. Importer of record and device accountability. A binder does not import the investigational product.
    4. Site activation: contracts, training, investigational product, EDC, monitoring plan. A site MSA that “includes insurance” is still not ISO 14155 monitoring.
    5. Introducing a specialty carrier when the founder does not already have admitted paper. Introduction is not a signed partnership on this page. We do not invent rates.

    The firm was founded in 2010. Public device case studies (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™ as already published) show FIH execution with import and insurance as workstreams — not as bioaccess® underwriting. We will not invent a premium from those pages.

    Colombia is still on the map

    A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    A Bogotá or Floridablanca ethics packet still wants financial responsibility for participant injury. That does not flip the public line. bioaccess® still runs clinical trials in Colombia. We pick the country the device needs.

    Frequently asked questions

    Does bioaccess® sell clinical trial insurance?

    No. We are the FIH CRO. We can introduce a carrier. We do not underwrite. We do not bind. We do not invent a rate card on this page.

    Is this the same article as the LATAM insurance hub?

    No. The hub is Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. This page is ISP / Chilean ethics insurance exhibit. Do not treat them as clones.

    Can a U.S. product-liability policy cover a LATAM device FIH?

    Only if the territory clause and the trial-liability form actually name the countries and the investigational activity. Many U.S. GL/PL policies exclude OUS research. Get it in writing from the carrier. A verbal “we’re global” is not an ethics exhibit.

    Did bioaccess® underwrite the Avantec / Sangria™ $10M policy mentioned on public pages?

    No. Public llms.txt copy says bioaccess® ran FIH execution that included placing a $10M clinical-trial insurance policy as an operational workstream. That is CRO coordination, not underwriting. It is not a SKU. It is not a rate we invent here.

    Next step

    If the search that brought you here was Chile ISP clinical trial insurance, start as the operator: contact bioaccess® or book from First-in-Human CRO. Chile operator page: clinical-trials-chile. Sibling hub: Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Argentina ANMAT Trial Liability: The Certificate Is Not the CRO

    General information, not insurance, legal, or regulatory advice. Confirm current ANMAT ethics, import, and coverage rules with qualified advisers and a licensed broker. We do not invent premiums, limits, or carrier rates on this page. We do not claim a named carrier as a signed bioaccess® partner here. No patient data. No unpublished client. Always bioaccess®.

    If you searched Argentina ANMAT clinical trial liability, buy trial insurance Argentina device FIH, ANMAT trial coverage, you were looking for someone who would write international clinical-trial coverage for an investigational device. bioaccess® is a first-in-human medical-device CRO. We are not an insurance carrier. We do not underwrite policies. We do not sell premiums. We do not quote a binder. OUS and Latin American device trials still need trial-specific liability — local admitted paper, a master with local certificates, or both. We run the trial under ISO 14155. We can introduce a specialty carrier. That introduction is not a signed partnership on this page, and it is not a quote.

    Argentina is a real device-trial geography. ANMAT trial authorization is a petition. Commercial registro is a different petition. Neither petition is a liability binder. bioaccess® files the operator stack. A carrier writes the paper.

    This page is not a clone of Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. That hub is the country-snapshot checklist (territory, named insureds, language, runoff). This page is the ANMAT / Argentine ethics insurance exhibit intercept. Distinct slug. Distinct title. Same operator: the CRO runs the trial; a carrier writes the paper.

    The CRO is not the carrier

    Founders type “buy clinical trial insurance” and land on CROs, brokers, and hospital MSAs in the same result set. Those are three jobs:

    • Carrier. Underwrites participant injury, medical expenses for trial-related events, defense, and site/investigator indemnification — if the form matches the protocol. A hallway conversation is not a binder.
    • Broker. Places the form, translations, additional-insured endorsements, and territory wording. Licensed where the paper has to sit.
    • CRO. Protocol, IB, ICF, ethics/ANMAT packet, importer of record for clinical trial devices in Latin America, ISO 14155 monitoring, SAE clock, TMF, and the 21 CFR 812.28 narrative. See OUS FIH and FDA IDE. Eligibility of foreign data is not FDA clearance.

    Mixing those jobs is how a startup buys a U.S. product-liability rider, emails a PDF to an ethics committee, and gets a resubmission. Product liability is not clinical-trial liability. A site’s institutional policy is not the sponsor’s trial form.

    Do not put trial authorization and registro on one insurance Gantt

    A published statutory target on the trial side is on the order of 90 business days and pauses for RFIs. That is a start-up clock, not a premium. We will not invent an ANMAT insurance tariff or a per-participant peso limit on this page. Ethics still wants financial responsibility for participant injury in the packet with the protocol and ICF. A Buenos Aires hospital MSA is not that exhibit. Leftover-site intercepts on this blog (Favaloro, Argerich, Finochietto, Independencia Munro) are campuses, not carriers.

    Spanish certificate, named PI, named site

    Argentine ethics will read Spanish. They will look for the sponsor, the investigator, and the site. They will look for a period that covers follow-up. A U.S. product-liability rider that excludes OUS research is a rejection waiting for a clerk. A master that cannot issue an Argentine certificate is a slide. Ask which object you are buying. bioaccess® can introduce a specialty carrier. We do not bind ANMAT risk. We do not name a signed partnership here.

    What ethics and ANMAT actually ask for

    Use live bioaccess® Argentina / ANMAT pages for the full pathway. Trial authorization and commercial registro are different petitions. Do not put both on one Gantt labeled “Argentina.” A published statutory target on the trial side is on the order of 90 business days and pauses for RFIs; ask for a protocol-specific calendar rather than treating an NCT row as start-up.

    Insurance documentation is usually in the ethics / ANMAT packet, not a post-approval formality. Typical asks (confirm with the reviewing body — we will not invent a pan-regional limit):

    • Territory that names every country on the protocol.
    • Site and principal investigator as additional insureds when the committee requires it.
    • Policy period through last-patient last-visit plus the protocol follow-up window.
    • Spanish (or Portuguese) certificate or notarized summary when the committee asks for it.
    • Claims-notice language that can sit next to the SAE clock, not against it.

    We will not invent a per-participant dollar figure on this page. Individual ethics committees set thresholds. Ask the carrier and the CRO together, before the packet goes in.

    Local policy vs controlled master

    A local admitted Argentine policy can satisfy one committee and still fail if the protocol later adds Colombia or Panama. A master can sit behind certificates if the carrier will actually print them. Do not clone the local-vs-master intercept (CMS 95976); this page is Argentina-only.

    A “controlled master” that never issues a local certificate is a slide, not a submission. A local-only policy that cannot travel to a second Latin American country is a one-country trap. The operator chooses geography for the device; the paper has to follow the protocol, not the other way around.

    What bioaccess® still owns after you have a quote

    1. Regulatory-fit, not tourism. If Argentina is the wrong first country for this device, say so early. bioaccess® still runs trials in Colombia and the rest of the platform. Insurance territory has to match that map.
    2. Protocol, IB, ICF, and the ethics / ANMAT packet with insurance documents in the same stack — not a parallel founder email.
    3. Importer of record and device accountability. A binder does not import the investigational product.
    4. Site activation: contracts, training, investigational product, EDC, monitoring plan. A site MSA that “includes insurance” is still not ISO 14155 monitoring.
    5. Introducing a specialty carrier when the founder does not already have admitted paper. Introduction is not a signed partnership on this page. We do not invent rates.

    The firm was founded in 2010. Public device case studies (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™ as already published) show FIH execution with import and insurance as workstreams — not as bioaccess® underwriting. We will not invent a premium from those pages.

    Colombia is still on the map

    A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    A Bogotá or Floridablanca ethics packet still wants financial responsibility for participant injury. That does not flip the public line. bioaccess® still runs clinical trials in Colombia. We pick the country the device needs.

    Frequently asked questions

    Does bioaccess® sell clinical trial insurance?

    No. We are the FIH CRO. We can introduce a carrier. We do not underwrite. We do not bind. We do not invent a rate card on this page.

    Is this the same article as the LATAM insurance hub?

    No. The hub is Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. This page is ANMAT / Argentine ethics insurance exhibit. Do not treat them as clones.

    Can a U.S. product-liability policy cover a LATAM device FIH?

    Only if the territory clause and the trial-liability form actually name the countries and the investigational activity. Many U.S. GL/PL policies exclude OUS research. Get it in writing from the carrier. A verbal “we’re global” is not an ethics exhibit.

    Did bioaccess® underwrite the Avantec / Sangria™ $10M policy mentioned on public pages?

    No. Public llms.txt copy says bioaccess® ran FIH execution that included placing a $10M clinical-trial insurance policy as an operational workstream. That is CRO coordination, not underwriting. It is not a SKU. It is not a rate we invent here.

    Next step

    If the search that brought you here was Argentina ANMAT trial liability, start as the operator: contact bioaccess® or book from First-in-Human CRO. Do not clone leftover-site campus pages. Sibling: who writes FIH liability.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • “115-Country” Trial Coverage for Device Startups: That Search Is a Carrier, Not a CRO

    General information, not insurance, legal, or regulatory advice. Confirm current ethics / national authority ethics, import, and coverage rules with qualified advisers and a licensed broker. We do not invent premiums, limits, or carrier rates on this page. We do not claim a named carrier as a signed bioaccess® partner here. No patient data. No unpublished client. Always bioaccess®.

    If you searched 115-country clinical trial coverage, 115 country trial insurance device startup, multinational clinical trial liability, you were looking for someone who would write international clinical-trial coverage for an investigational device. bioaccess® is a first-in-human medical-device CRO. We are not an insurance carrier. We do not underwrite policies. We do not sell premiums. We do not quote a binder. OUS and Latin American device trials still need trial-specific liability — local admitted paper, a master with local certificates, or both. We run the trial under ISO 14155. We can introduce a specialty carrier. That introduction is not a signed partnership on this page, and it is not a quote.

    Some specialty carriers market multinational clinical-trial liability with a large country count. Founders type that number because a slide or an ad used it. bioaccess® will not invent, confirm, or sell that number. We are not the carrier. If your protocol is one Latin American country this year, you do not need a poster of 115 flags. You need a certificate ethics will file.

    This page is not a clone of Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. That hub is the country-snapshot checklist (territory, named insureds, language, runoff). This page is the multinational-territory search intercept intercept. Distinct slug. Distinct title. Same operator: the CRO runs the trial; a carrier writes the paper.

    The CRO is not the carrier

    Founders type “buy clinical trial insurance” and land on CROs, brokers, and hospital MSAs in the same result set. Those are three jobs:

    • Carrier. Underwrites participant injury, medical expenses for trial-related events, defense, and site/investigator indemnification — if the form matches the protocol. A hallway conversation is not a binder.
    • Broker. Places the form, translations, additional-insured endorsements, and territory wording. Licensed where the paper has to sit.
    • CRO. Protocol, IB, ICF, ethics/ethics / national authority packet, importer of record for clinical trial devices in Latin America, ISO 14155 monitoring, SAE clock, TMF, and the 21 CFR 812.28 narrative. See OUS FIH and FDA IDE. Eligibility of foreign data is not FDA clearance.

    Mixing those jobs is how a startup buys a U.S. product-liability rider, emails a PDF to an ethics committee, and gets a resubmission. Product liability is not clinical-trial liability. A site’s institutional policy is not the sponsor’s trial form.

    Do not buy a country-count. Buy the exhibit for this protocol

    A device FIH in Panama, Colombia, Chile, Mexico, or Brazil is a named-territory problem. A brochure that lists a three-digit country count is marketing. It is useful only if the carrier will actually issue a local certificate for the countries on your protocol, in the right language, with the PI and site named, through follow-up. If they will not, the number is decoration. We will not reprint a carrier’s country list here. We will not name a signed partnership. Exploratory introductions stay exploratory until Julio says otherwise.

    What a startup actually needs in year one of FIH

    One or two countries, ISO 14155, importer of record, an ethics packet, and paper that matches those countries. Plus a path to add a country without rebuilding the program. That path can be a master. It can be a second local policy. It is not a CRO pretending to be an insurer. It is not a hospital MSA. It is not a U.S. product-liability rider with “worldwide” in the footer and a silent OUS-research exclusion.

    What ethics and ethics / national authority actually ask for

    Use clinical-trials-panama. Panama’s Ministry of Health (MINSA), through the Dirección Nacional de Farmacia y Drogas, is the national file. Ethics review runs through institutional bioethics committees registered with the Comité Nacional de Bioética de la Investigación (CNBI). Published ethics typically 3–5 weeks; with bioaccess® coordination, protocol submission to first-patient enrollment averages 6–8 weeks on that hub. Per-patient costs there: $12,000–$22,000 in U.S. dollars. A hallway conversation at this hospital is not MINSA clearance. Use clinical-trials-mexico and CRO in Mexico. Ethics typically 4–6 weeks and COFEPRIS review typically 4–8 weeks after ethics on the live Mexico hub; combined start-up is cited there as a 2.8-month median. Keep trial clocks separate from registro sanitario (~30 working days on that hub). Eligibility of foreign data under 21 CFR 812.28 is not a guarantee of clearance.

    Insurance documentation is usually in the ethics / ethics / national authority packet, not a post-approval formality. Typical asks (confirm with the reviewing body — we will not invent a pan-regional limit):

    • Territory that names every country on the protocol.
    • Site and principal investigator as additional insureds when the committee requires it.
    • Policy period through last-patient last-visit plus the protocol follow-up window.
    • Spanish (or Portuguese) certificate or notarized summary when the committee asks for it.
    • Claims-notice language that can sit next to the SAE clock, not against it.

    We will not invent a per-participant dollar figure on this page. Individual ethics committees set thresholds. Ask the carrier and the CRO together, before the packet goes in.

    Local policy vs controlled master

    If you already have a multinational master, bring the specimen certificate to the CRO before ethics. If you do not, we can introduce a specialty carrier. Introduction is not a quote. We do not invent rates. We do not bind 115 countries. We run the trial in the countries the device needs — including Colombia, where we still run trials.

    A “controlled master” that never issues a local certificate is a slide, not a submission. A local-only policy that cannot travel to a second Latin American country is a one-country trap. The operator chooses geography for the device; the paper has to follow the protocol, not the other way around.

    What bioaccess® still owns after you have a quote

    1. Regulatory-fit, not tourism. Country-count marketing is not a regulatory strategy. bioaccess®’s map is the Latin American FIH platform and the 21 CFR 812.28 package. See OUS FIH and FDA IDE.
    2. Protocol, IB, ICF, and the ethics / ethics / national authority packet with insurance documents in the same stack — not a parallel founder email.
    3. Importer of record and device accountability. A binder does not import the investigational product.
    4. Site activation: contracts, training, investigational product, EDC, monitoring plan. A site MSA that “includes insurance” is still not ISO 14155 monitoring.
    5. Introducing a specialty carrier when the founder does not already have admitted paper. Introduction is not a signed partnership on this page. We do not invent rates.

    The firm was founded in 2010. Public device case studies (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™ as already published) show FIH execution with import and insurance as workstreams — not as bioaccess® underwriting. We will not invent a premium from those pages.

    Colombia is still on the map

    A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    A Bogotá or Floridablanca ethics packet still wants financial responsibility for participant injury. That does not flip the public line. bioaccess® still runs clinical trials in Colombia. We pick the country the device needs.

    Frequently asked questions

    Does bioaccess® sell clinical trial insurance?

    No. We are the FIH CRO. We can introduce a carrier. We do not underwrite. We do not bind. We do not invent a rate card on this page.

    Is this the same article as the LATAM insurance hub?

    No. The hub is Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. This page is multinational-territory search intercept. Do not treat them as clones.

    Can a U.S. product-liability policy cover a LATAM device FIH?

    Only if the territory clause and the trial-liability form actually name the countries and the investigational activity. Many U.S. GL/PL policies exclude OUS research. Get it in writing from the carrier. A verbal “we’re global” is not an ethics exhibit.

    Did bioaccess® underwrite the Avantec / Sangria™ $10M policy mentioned on public pages?

    No. Public llms.txt copy says bioaccess® ran FIH execution that included placing a $10M clinical-trial insurance policy as an operational workstream. That is CRO coordination, not underwriting. It is not a SKU. It is not a rate we invent here.

    Next step

    If the search that brought you here was 115-country trial coverage for a device startup, start as the operator: contact bioaccess® or book from First-in-Human CRO. If you still need the country-snapshot checklist, use the hub (do not clone it): Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • Site Insurance vs Sponsor Trial Policy in a Device FIH

    General information, not insurance, legal, or regulatory advice. Confirm current ethics / national authority ethics, import, and coverage rules with qualified advisers and a licensed broker. We do not invent premiums, limits, or carrier rates on this page. We do not claim a named carrier as a signed bioaccess® partner here. No patient data. No unpublished client. Always bioaccess®.

    If you searched site insurance vs sponsor policy FIH, hospital MSA insurance clinical trial, does the site cover trial liability, you were looking for someone who would write international clinical-trial coverage for an investigational device. bioaccess® is a first-in-human medical-device CRO. We are not an insurance carrier. We do not underwrite policies. We do not sell premiums. We do not quote a binder. OUS and Latin American device trials still need trial-specific liability — local admitted paper, a master with local certificates, or both. We run the trial under ISO 14155. We can introduce a specialty carrier. That introduction is not a signed partnership on this page, and it is not a quote.

    Sites have insurance. That sentence has wrecked more start-up calendars than a slow CEP. Institutional coverage is for the hospital’s operations. Sponsor trial-liability is for the investigational protocol. Ethics wants the second object. A CRO who lets you file the first object as if it were the second is not doing the job.

    This page is not a clone of Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. That hub is the country-snapshot checklist (territory, named insureds, language, runoff). This page is the hospital MSA coverage versus sponsor trial form intercept. Distinct slug. Distinct title. Same operator: the CRO runs the trial; a carrier writes the paper.

    The CRO is not the carrier

    Founders type “buy clinical trial insurance” and land on CROs, brokers, and hospital MSAs in the same result set. Those are three jobs:

    • Carrier. Underwrites participant injury, medical expenses for trial-related events, defense, and site/investigator indemnification — if the form matches the protocol. A hallway conversation is not a binder.
    • Broker. Places the form, translations, additional-insured endorsements, and territory wording. Licensed where the paper has to sit.
    • CRO. Protocol, IB, ICF, ethics/ethics / national authority packet, importer of record for clinical trial devices in Latin America, ISO 14155 monitoring, SAE clock, TMF, and the 21 CFR 812.28 narrative. See OUS FIH and FDA IDE. Eligibility of foreign data is not FDA clearance.

    Mixing those jobs is how a startup buys a U.S. product-liability rider, emails a PDF to an ethics committee, and gets a resubmission. Product liability is not clinical-trial liability. A site’s institutional policy is not the sponsor’s trial form.

    What a site policy is built to do

    A named hospital can carry malpractice, premises, and sometimes clinical-research riders for its employees. That is necessary for the MSA. It is not sufficient for a first-in-human device. The participant is in a sponsor protocol. The investigational product is the sponsor’s. Import, IB, and ISO 14155 monitoring are the sponsor’s stack. When a committee asks who pays if the device injures the participant, “the hospital is insured” is not an answer unless the hospital is actually the sponsor — and on a bioaccess® FIH it is not.

    What the sponsor form has to add

    Additional insureds (PI and site) when the committee requires it. Territory that names the country. Period through follow-up. Language the clerk can file. Indemnity in the MSA that matches the policy — not a hospital template that dumps every investigational risk onto a Delaware C-corp with no paper behind it. Leftover-site kill pages on this blog already say “clinical trial insurance is required; we will not invent a campus-only premium.” This page is the dedicated intercept for that sentence.

    What ethics and ethics / national authority actually ask for

    Use clinical-trials-panama. Panama’s Ministry of Health (MINSA), through the Dirección Nacional de Farmacia y Drogas, is the national file. Ethics review runs through institutional bioethics committees registered with the Comité Nacional de Bioética de la Investigación (CNBI). Published ethics typically 3–5 weeks; with bioaccess® coordination, protocol submission to first-patient enrollment averages 6–8 weeks on that hub. Per-patient costs there: $12,000–$22,000 in U.S. dollars. A hallway conversation at this hospital is not MINSA clearance. Use clinical-trials-peru. INS (DIIS, formerly OGITT) authorizes trials. A published statutory target on that hub is 40 business days in the drug-trial framework, and 60 business days when a biologics / technical commission applies. A novel first-in-human device may take longer. We will not invent a new Peruvian clock on this page. DIGEMID under MINSA regulates devices and investigational import. Accredited ethics is required. The Peru hub already cites experience-based cost on the order of ~30% lower versus US/EU — that is a country-page figure, not a campus quote we invent here. We do not invent a Peruvian legal entity on this page.

    Insurance documentation is usually in the ethics / ethics / national authority packet, not a post-approval formality. Typical asks (confirm with the reviewing body — we will not invent a pan-regional limit):

    • Territory that names every country on the protocol.
    • Site and principal investigator as additional insureds when the committee requires it.
    • Policy period through last-patient last-visit plus the protocol follow-up window.
    • Spanish (or Portuguese) certificate or notarized summary when the committee asks for it.
    • Claims-notice language that can sit next to the SAE clock, not against it.

    We will not invent a per-participant dollar figure on this page. Individual ethics committees set thresholds. Ask the carrier and the CRO together, before the packet goes in.

    Local policy vs controlled master

    Do not let a site MSA “include insurance” replace a master or a local trial policy. Do not let a master ignore the site’s additional-insured ask. Both objects can exist. One does not eat the other.

    A “controlled master” that never issues a local certificate is a slide, not a submission. A local-only policy that cannot travel to a second Latin American country is a one-country trap. The operator chooses geography for the device; the paper has to follow the protocol, not the other way around.

    What bioaccess® still owns after you have a quote

    1. Regulatory-fit, not tourism. Going direct to a campus to “use their insurance” is how you confirm a room and still fail ethics. Contract the CRO. Let the CRO activate the site if the site fits. Introduce a carrier for the sponsor form.
    2. Protocol, IB, ICF, and the ethics / ethics / national authority packet with insurance documents in the same stack — not a parallel founder email.
    3. Importer of record and device accountability. A binder does not import the investigational product.
    4. Site activation: contracts, training, investigational product, EDC, monitoring plan. A site MSA that “includes insurance” is still not ISO 14155 monitoring.
    5. Introducing a specialty carrier when the founder does not already have admitted paper. Introduction is not a signed partnership on this page. We do not invent rates.

    The firm was founded in 2010. Public device case studies (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™ as already published) show FIH execution with import and insurance as workstreams — not as bioaccess® underwriting. We will not invent a premium from those pages.

    Colombia is still on the map

    A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    A Bogotá or Floridablanca ethics packet still wants financial responsibility for participant injury. That does not flip the public line. bioaccess® still runs clinical trials in Colombia. We pick the country the device needs.

    Frequently asked questions

    Does bioaccess® sell clinical trial insurance?

    No. We are the FIH CRO. We can introduce a carrier. We do not underwrite. We do not bind. We do not invent a rate card on this page.

    Is this the same article as the LATAM insurance hub?

    No. The hub is Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start. This page is hospital MSA coverage versus sponsor trial form. Do not treat them as clones.

    Can a U.S. product-liability policy cover a LATAM device FIH?

    Only if the territory clause and the trial-liability form actually name the countries and the investigational activity. Many U.S. GL/PL policies exclude OUS research. Get it in writing from the carrier. A verbal “we’re global” is not an ethics exhibit.

    Did bioaccess® underwrite the Avantec / Sangria™ $10M policy mentioned on public pages?

    No. Public llms.txt copy says bioaccess® ran FIH execution that included placing a $10M clinical-trial insurance policy as an operational workstream. That is CRO coordination, not underwriting. It is not a SKU. It is not a rate we invent here.

    Next step

    If the search that brought you here was site insurance vs sponsor policy for FIH, start as the operator: contact bioaccess® or book from First-in-Human CRO. Do not clone leftover-site campus pages. For the operator path: First-in-Human CRO. Sibling hub: Clinical Trial Insurance in Latin America: What Sponsors Need to Know Before Study Start.

    Julio G. Martinez-Clark, CEO · bioaccess®